Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Clinical features related to statin-associated muscle symptoms.

Ochs-Balcom HM, Nguyen LM, Ma C, Isackson PJ, Luzum JA, Kitzmiller JP, Tarnopolsky M, Weisman M, Christopher-Stine L, Peltier W, Wortmann RL, Vladutiu GD.

Muscle Nerve. 2019 May;59(5):537-543. doi: 10.1002/mus.26397. Epub 2019 Jan 11.

PMID:
30549046
2.

The causes of drug-induced muscle toxicity.

Jones JD, Kirsch HL, Wortmann RL, Pillinger MH.

Curr Opin Rheumatol. 2014 Nov;26(6):697-703. doi: 10.1097/BOR.0000000000000108. Review.

PMID:
25191992
3.

Noninflammatory myopathies.

Baer AN, Wortmann RL.

Rheum Dis Clin North Am. 2013 May;39(2):457-79. doi: 10.1016/j.rdc.2013.02.006. Epub 2013 Mar 16. Review.

PMID:
23597974
4.

Latest evidence on gout management: what the clinician needs to know.

Burns CM, Wortmann RL.

Ther Adv Chronic Dis. 2012 Nov;3(6):271-86. doi: 10.1177/2040622312462056.

5.

Hyperuricemia and gout: new concepts in diagnosis and management.

Doghramji PP, Wortmann RL.

Postgrad Med. 2012 Nov;124(6):98-109. doi: 10.3810/pgm.2012.11.2616. Review.

PMID:
23322143
6.

The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

Coley W, Rayavarapu S, Pandey GS, Sabina RL, Van der Meulen JH, Ampong B, Wortmann RL, Rawat R, Nagaraju K.

Arthritis Rheum. 2012 Nov;64(11):3750-9. doi: 10.1002/art.34625.

7.

When should a rheumatologist suspect a mitochondrial myopathy?

Albert DA, Cohen JA, Burns CM, Hickey WF, Prock TL, James JA, Rhodes CH, Wortmann RL.

Arthritis Care Res (Hoboken). 2011 Nov;63(11):1497-502. doi: 10.1002/acr.20592. Review. No abstract available.

8.

Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS.

Isackson PJ, Ochs-Balcom HM, Ma C, Harley JB, Peltier W, Tarnopolsky M, Sripathi N, Wortmann RL, Simmons Z, Wilson JD, Smith SA, Barboi A, Fine E, Baer A, Baker S, Kaufman K, Cobb B, Kilpatrick JR, Vladutiu GD.

Muscle Nerve. 2011 Oct;44(4):531-8. doi: 10.1002/mus.22115. Epub 2011 Aug 8.

9.

Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.

Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL.

Mol Genet Metab. 2011 Sep-Oct;104(1-2):167-73. doi: 10.1016/j.ymgme.2011.07.001. Epub 2011 Jul 12.

10.

Drugs causing muscle disease.

Mor A, Wortmann RL, Mitnick HJ, Pillinger MH.

Rheum Dis Clin North Am. 2011 May;37(2):219-31, vi. doi: 10.1016/j.rdc.2011.01.005. Review.

PMID:
21444021
11.

Preface: myopathies.

Wortmann RL.

Rheum Dis Clin North Am. 2011 May;37(2):ix-x. doi: 10.1016/j.rdc.2011.02.001. No abstract available.

PMID:
21444015
12.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107
13.

Gout therapeutics: new drugs for an old disease.

Burns CM, Wortmann RL.

Lancet. 2011 Jan 8;377(9760):165-77. doi: 10.1016/S0140-6736(10)60665-4. Epub 2010 Aug 16. Review.

PMID:
20719377
14.

Drug-induced myopathies.

Mor A, Mitnick HJ, Pillinger MH, Wortmann RL.

Bull NYU Hosp Jt Dis. 2009;67(4):358-69. Review.

PMID:
20001939
15.

Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA.

Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF.

J Rheumatol. 2009 Dec;36(12):2704-10. doi: 10.3899/jrheum.090549. Epub 2009 Nov 16.

16.

Hydroxychloroquine and colchicine induced myopathy.

Lonesky TA, Kreuter JD, Wortmann RL, Rhodes CH.

J Rheumatol. 2009 Nov;36(11):2617-8. doi: 10.3899/jrheum.081315. No abstract available.

PMID:
19893064
17.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

18.

Drug-induced arthritic and connective tissue disorders.

Mor A, Pillinger MH, Wortmann RL, Mitnick HJ.

Semin Arthritis Rheum. 2008 Dec;38(3):249-64. doi: 10.1016/j.semarthrit.2007.10.001. Epub 2007 Dec 31. Review.

PMID:
18166218
19.

Management of gout in older adults: barriers to optimal control.

Hoskison KT, Wortmann RL.

Drugs Aging. 2007;24(1):21-36. Review.

PMID:
17233545
20.

Myotoxicity associated with lipid-lowering drugs.

Baer AN, Wortmann RL.

Curr Opin Rheumatol. 2007 Jan;19(1):67-73. Review.

PMID:
17143099
21.

The management of gout: it should be crystal clear.

Wortmann RL.

J Rheumatol. 2006 Oct;33(10):1921-2. No abstract available.

PMID:
17014007
22.

Dermatomyositis.

Callen JP, Wortmann RL.

Clin Dermatol. 2006 Sep-Oct;24(5):363-73. Review.

PMID:
16966018
23.

Advances in the management of gout and hyperuricaemia.

Hoskison TK, Wortmann RL.

Scand J Rheumatol. 2006 Jul-Aug;35(4):251-60. Review.

PMID:
16882587
24.

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS.

Muscle Nerve. 2006 Aug;34(2):153-62.

PMID:
16671104
25.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

26.

Academic rheumatology: like it, leave it, or fight to change it.

Wortmann RL.

Arthritis Rheum. 2005 Oct 15;53(5):643-5. No abstract available.

27.

Dose-related statin myopathy: is it an issue?

Wortmann RL.

Cleve Clin J Med. 2005 Sep;72(9):751-3, 756. No abstract available.

PMID:
16193823
28.

Recent advances in the management of gout and hyperuricemia.

Wortmann RL.

Curr Opin Rheumatol. 2005 May;17(3):319-24. Review.

PMID:
15838244
29.

Frequency of myopathy in patients receiving lovastatin.

Wortmann RL, Tipping RW, Levine JG, Melin JM.

Am J Cardiol. 2005 Apr 15;95(8):983-5. Review.

PMID:
15820170
30.
31.

Polymyositis: an overdiagnosed entity.

Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV.

Neurology. 2004 Jul 27;63(2):402; author reply 403. No abstract available.

PMID:
15277657
32.
33.

Differentiating idiopathic inflammatory myopathies from metabolic myopathies.

Wortmann RL, DiMauro S.

Rheum Dis Clin North Am. 2002 Nov;28(4):759-78. Review.

PMID:
12506771
34.

Lipid-lowering agents and myopathy.

Wortmann RL.

Curr Opin Rheumatol. 2002 Nov;14(6):643-7. Review.

PMID:
12410084
35.

Gout and hyperuricemia.

Wortmann RL.

Curr Opin Rheumatol. 2002 May;14(3):281-6. Review.

PMID:
11981327
36.

The clinical laboratory evaluation of the patient with noninflammatory myopathy.

Wortmann RL, Vladutiu GD.

Curr Rheumatol Rep. 2001 Aug;3(4):310-6. Review.

PMID:
11470050
37.

Metabolic and mitochondrial myopathies.

Wortmann RL.

Curr Opin Rheumatol. 1999 Nov;11(6):462-7. Review.

PMID:
10551669
38.

Effective management of gout: an analogy.

Wortmann RL.

Am J Med. 1998 Dec;105(6):513-4. Review. No abstract available.

PMID:
9870838
39.

The clinical philosophy of internal medicine.

Wortmann RL.

Am J Med. 1998 Apr;104(4):323-6. No abstract available.

PMID:
9576402
40.

Muscle disease symptoms: evaluation and significance.

Wortmann RL.

Bull Rheum Dis. 1994 Oct;43(6):1-4. No abstract available.

PMID:
7987432
41.

Searching for the cause of fibromyalgia: is there a defect in energy metabolism?

Wortmann RL.

Arthritis Rheum. 1994 Jun;37(6):790-3. No abstract available.

PMID:
8003049
42.

The dilemma of treating patients with inclusion body myositis.

Wortmann RL.

J Rheumatol. 1992 Sep;19(9):1327-9. No abstract available.

PMID:
1331440
43.

Joint replacement. The primary care physician's role.

Norton AJ, Wortmann RL.

Postgrad Med. 1992 Mar;91(4):267-70, 273-6.

PMID:
1546016
44.

Metabolic myopathies.

Wortmann RL.

Curr Opin Rheumatol. 1991 Dec;3(6):925-33. Review.

PMID:
1772746
45.

Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout.

McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL.

Arthritis Rheum. 1991 Dec;34(12):1489-94.

PMID:
1747133
46.

Pathogenesis of rheumatoid arthritis: basis for future therapies.

Wortmann RL.

Semin Arthritis Rheum. 1991 Oct;21(2 Suppl 1):35-9. Review.

PMID:
1749947
48.

Diagnosis, pathogenesis, and management of reflex sympathetic dystrophy syndrome.

Rosenthal AK, Wortmann RL.

Compr Ther. 1991 Jun;17(6):46-50. Review. No abstract available.

PMID:
1934988
49.

Basis for the chondro-osseous dysplasia associated with adenosine deaminase deficiency: selective toxicity to immature chondrocytes.

Wortmann RL, Tekkanat KK, Veum JA, Meyer RA Jr, Hood JO, Horton WA.

Adv Exp Med Biol. 1991;309B:265-8. No abstract available.

PMID:
1781380
50.

Molecular analysis of acquired myoadenylate deaminase deficiency in polymyositis (idiopathic inflammatory myopathy).

Sabina RL, Sulaiman AR, Wortmann RL.

Adv Exp Med Biol. 1991;309B:203-5. No abstract available.

PMID:
1781368

Supplemental Content

Loading ...
Support Center